E
Elisabeth Müller-Holzner
Researcher at Innsbruck Medical University
Publications - 90
Citations - 5109
Elisabeth Müller-Holzner is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 38, co-authored 90 publications receiving 4787 citations. Previous affiliations of Elisabeth Müller-Holzner include BC Cancer Agency & University of Innsbruck.
Papers
More filters
Journal ArticleDOI
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
Dominik Wolf,Anna Maria Wolf,Holger Rumpold,Heidi Fiegl,Alain G. Zeimet,Elisabeth Müller-Holzner,Martina Deibl,Guenther Gastl,Eberhard Gunsilius,Christian Marth +9 more
TL;DR: High expression levels of FoxP3 might represent a surrogate marker for an immunosuppressive milieu contributing to tumor immune escape and strategies selectively depleting Treg might improve the antitumor activity of endogenously arising tumor-reactive T cells and immunotherapies using vaccines or antibodies.
Journal Article
hCDC4 Gene Mutations in Endometrial Cancer
Charles Spruck,Heimo Strohmaier,Olle Sangfelt,Hannes M. Müller,Michael Hubalek,Elisabeth Müller-Holzner,Christian Marth,Martin Widschwendter,Steven I. Reed +8 more
TL;DR: The results show that the hCDC4 gene is mutated in primary human tumors and suggest that it may function as a tumor suppressor in the genesis of many human cancers.
Journal ArticleDOI
DNA Hypomethylation and Ovarian Cancer Biology
Martin Widschwendter,Guanchao Jiang,Christian B. Woods,Hannes M. Müller,Heidi Fiegl,Georg Goebel,Christian Marth,Elisabeth Müller-Holzner,Alain G. Zeimet,Peter W. Laird,Melanie Ehrlich +10 more
TL;DR: It is concluded that satellite DNA hypomethylation is an important issue in ovarian carcinogenesis as demonstrated by an increase from non-neoplastic tissue toward ovarian cancer; an increase within the ovarian cancer group toward advanced grade and stage; and the finding that strong hypometHylation was an independent marker of poor prognosis.
Journal ArticleDOI
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
Gudrun Windbichler,H. Hausmaninger,W. Stummvoll,A.H. Graf,Christian Kainz,J Lahodny,U. Denison,Elisabeth Müller-Holzner,Christian Marth +8 more
TL;DR: With acceptable toxicity, the inclusion of IFN-γ in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival.
Journal ArticleDOI
L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation
Alain G. Zeimet,Daniel Reimer,Monica Huszar,Boris Winterhoff,Ulla Puistola,Samira Abdel Azim,Elisabeth Müller-Holzner,Alon Ben-Arie,Léon C van Kempen,Edgar Petru,Stephan W Jahn,Yvette P. Geels,Leon F.A.G. Massuger,Frédéric Amant,Stephan Polterauer,Elisa Lappi-Blanco,Johan Bulten,Alexandra Meuter,Staci Tanouye,Peter Oppelt,Monika Stroh-Weigert,Alexander Reinthaller,Andrea Mariani,Werner O. Hackl,Michael Netzer,Uwe Schirmer,Ignace Vergote,Peter Altevogt,Christian Marth,Mina Fogel +29 more
TL;DR: L1CAM has been shown to be the best-ever published prognostic factor in FIGO stage I, type I endometrial cancers and shows clear superiority over the standardly used multifactor risk score.